Cansino Biologics Inc. (6185)

Hong Kong
139.30
-14.10(-9.19%)
  • Volume:
    1,135,816
  • Bid/Ask:
    139.20/139.40
  • Day's Range:
    138.30 - 152.00

6185 Overview

Prev. Close
153.4
Day's Range
138.3-152
Revenue
2.54B
Open
148
52 wk Range
138.3-450
EPS
3.12
Volume
1,135,816
Market Cap
53.7B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,170,690
P/E Ratio
44.58
Beta
-
1-Year Change
-17.08%
Shares Outstanding
247,449,899
Next Earnings Date
Mar 30, 2022
What is your sentiment on Cansino Biologics Inc.?
or
Market is currently closed. Voting is open during market hours.

Cansino Biologics Inc. Company Profile

Employees
726
Market
Hong Kong

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People’s Republic of China.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • 1st TP 350 gogogo
    0
    • UBS Trims CANSINOBIO-B TP to $400; Rated Buy
      0
      • It's time..
        0
    • Time to buy again
      0
      • Biotech stocks will go strong
        0
    • 🚀🚀🚀🚀🚀🚀🚀🚀
      0
      • When announce efficacy?
        0
        • Buy
          0
          • Where can i trade this
            0
            • flying soon from 182 to 300 real soon
              0
              • You did tell us so!
                0
            • One of the most volatile stock where high daily speculation is going on.
              0
              • they will be the first with an effective safe vaccine
                4
                • I agree with u
                  0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.